A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 22 Aug 2017 Status changed from active, no longer recruiting to completed.